ArCHitect Therapeutics

Biotech · Private

Oral small-molecule therapeutics designed via C-H bond activation chemistry to target disease drivers

architecttherapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2201NEONEURON, LLC——
2202PEPTIFORGE, INC——
2203BIOPROCESSING INNOVATIVE COMPANY INC——
2204ArCHitect Therapeutics——
2205SHAL TECHNOLOGIES, INC.——
2206Cognosetta, Inc.——
2207RJS Biologics L.L.C.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Spiro Heterocyclic CDK2 Inhibitorsapplication
  • Substituted Pyridines And Pyrimidinesapplication
  • Substituted Pyridines And Pyrimidinesapplication
  • Spiro Heterocyclic CDK2 Inhibitorsapplication
  • Trisubstituted Pyridines And Pyrimidinesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.